• NVIDIA GTC Panel Explores the Role of Generative AI in Medicine

    Bio-IT World | During the NVIDIA GTC conference held at the San Jose Convention Center and online March 18-21, NVIDIA CEO Jensen Huang highlighted an array of advancements, including new foundation models coming to NVIDIA BioNeMo, a collaboration with Johnson & Johnson MedTech to expand AI’s role in surgical settings, and the launch of over two dozen generative AI microservices to advance areas like digital health, medical technology, and drug discovery.

    Apr 9, 2024
  • Bio-IT World Names 2024 Best of Show Finalists, People’s Choice Contenders

    Bio-IT World | Bio-IT World announced the 2024 Best of Show Finalists and People’s Choice Contenders today, highlighting 26 new products from 27 different companies that will be on display at the Bio-IT World Conference and Expo, April 15-17, in Boston. The Best of Show Awards will honor several new products live at the event during the Best of Show Awards Reception beginning at 5:15 on Tuesday, April 16.

    Apr 8, 2024
  • Enhancing CRISPR: Utilizing Single-Cell Multiomics for CRISPR-based Drug Product Analysis

    Bio-IT World | The pace at which CRISPR has transitioned from a research tool to a therapeutic modality is remarkable. Initially targeting genetic diseases, CRISPR holds tremendous promise across various indications, rapidly expanding into oncology and infectious diseases, indicating CRISPR's vast and continual evolution as a modality.

    Apr 5, 2024
  • RNA-Protein Complex Contributing To ‘Background Autoimmunity’ In Women

    Bio-IT World | The single biggest risk factor for autoimmune disease is being biologically a female and many explanations have been proposed as to why that is, among them sex hormones and the X chromosome with its large number of immune-related genes.

    Apr 3, 2024
  • Spatial Biology: Market Outlook Across the Drug Discovery Pipeline

    Bio-IT World | Miguel Edwards, a partner at DeciBio Consulting, broke down the market outlook for spatial biology at last week’s Precision Medicine TriConference. “We think about this market really as opening up a new dimension of biological insight into tissue analysis,” Edwards said. “You’re seeing the excitement and promise for really improving our understanding of fundamental biology and really driving better therapeutics and better diagnostics.”

    Apr 2, 2024
  • Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support

    Bio-IT World | In the newest episode of Trends from the Trenches, host Stan Gloss speaks with La Barge about his unique perspective on growing biotech businesses. La Barge delves into the challenges he and his team face in gene therapy advancement and how a company—especially one just starting out—can pave the path to successful research.

    Mar 28, 2024
  • PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More

    Bio-IT World | PacBio announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders; Owkin and Sanofi take on immunology; new products from Beckman Coulter, Arrayjet, and PatientSight; and more.

    Mar 27, 2024
  • Follow the Money: In Vivo CAR-T Candidate Development, Modular T Cell Engagers, Wearable Tech, More

    Bio-IT World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations, resulting in off-the-shelf, antibody-like medicines that can specifically target a wide variety of hard-to-treat tumor types; Ultrahuman plan to further manufacture capacity and deepen research in the health tracking space; and more.

    Mar 26, 2024
  • #BioITExpo: Agenda Highlights for the 2024 Bio-IT World Conference & Expo

    Bio-IT World | With the Bio-IT World Conference & Expo less than a month away, we are busy marking our schedules and planning our week. This year the event shifts a day, starting on Monday, and offers six deep-dive full day symposia on topics including automation, quantum computing, knowledge graphs, and more.

    Mar 22, 2024
  • New Basement Membrane Extract Discovery Lifts Uncertainty For Clinical Trials

    Bio-IT World | But do different BME brands affect drug responses and gene expressions in organoids? To determine the answer, researchers at the Salk Institute tested out different BMEs to see their effects on pancreatic cancer organoids.

    Mar 21, 2024
  • 2024 Innovative Practices Winners in Informatics, Collaboration, Clinical IT, Genomics

    Bio-IT World | Bio-IT World today announced the 2024 Innovative Practices Awards winners. Six projects were honored. Companies driving the winning entries included AstraZeneca, DNAnexus, Pistoia Alliance, Regeneron, Tempus, and UK Biobank.

    Mar 19, 2024
  • Five Global Teams Tackling Cancer Grand Challenges

    Bio-IT World | Cancer Grand Challenges—a global funding initiative co-founded by the National Cancer Institute and Cancer Research UK—has announced five new global teams selected to each receive up to $25M over five years to take on four of cancer’s toughest challenges.

    Mar 14, 2024
  • Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS

    Bio-IT World | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less.

    Mar 13, 2024
  • Biology-Based Diagnostic Criteria For Parkinson’s Disease Research

    Bio-IT World | Scientists from a trio of countries are calling for a new, more comprehensive way of classifying Parkinson’s disease for diagnostic research purposes that considers an individual’s biology. The disorder might thereby be detected before patients have any symptoms, as is now the case for cancer and diabetes.

    Mar 12, 2024
  • Human Biomolecular Atlas Program Update

    Bio-IT World | The NIH Common Fund Human Biomolecular Atlas Program (HuBMAP) is trying to map—to create a reference atlas—of the 37 trillion human cells in our body. Work is underway on a male and female reference atlas that could help us better understand what is normal when we are healthy and help shed light on how we change as we age or as other bodily changes, such as pregnancy, occur.

    Mar 7, 2024
  • Adama Ibrahim on Embracing Change and Overcoming Resistance

    Bio-IT World | Change naturally happens everywhere. Yet, it is often met with resistance—sometimes even with outright hostility. But in an ever-evolving world, change is needed to inspire innovation and create new opportunities, and the biotech industry is no different. The question is, how do we overcome resistance?

    Mar 6, 2024
  • Bio-IT World Launches Exclusive Venture, Investing Event

    Bio-IT World | The Bio-IT World Conference & Expo has launched a new co-located event this year—the Bio-IT World Venture, Innovation, and Partnering Conference, held on Wednesday, April 17, overlapping with the last day of the Bio-IT World Conference.

    Mar 5, 2024
  • Oxford Nanopore and Lonza Team Up, Medidata and Sanofi Vaccines Collaborate, More

    Bio-IT World | Oxford Nanopore and Lonza have teamed up to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA; Parse updates whole transcriptome kit; and more.

    Feb 29, 2024
  • Ginkgo Bioworks Announces Three Acquisitions

    Bio-IT World | Ginkgo Bioworks announced three acquisitions today: Reverie Labs, Proof Diagnostics, and Patch Biosciences. The acquisitions will expand Ginkgo’s capabilities for large-scale AI foundation models, its library of RNA programmable, non-Cas enzymes, and its machine learning models and downstream assays.

    Feb 28, 2024
  • Follow the Money: Cancer Early Detection Tests, Self-Sampling Solutions Expansion, Multiple Product Advancement

    Bio-IT World | Freenome will advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform; Capitainer plans to advance its journey toward becoming the foremost provider of self-sampling solutions with new funding, including scaling up production capacity, enhancing sales and marketing strategies, and launching new products; COUR will advance multiple, wholly owned product candidates that leverage the company’s immune tolerance platform, including Phase 2a proof-of-concept clinical studies in Myasthenia Gravis and Type 1 Diabetes, and other pipeline opportunities; and more.

    Feb 28, 2024